Nephrology

Diabetes

Questions discussed in this category

Do you favor Sotagliflozin over SGLT2i alone for cardiovascular risk reduction in patients with Type 2 diabetes and chronic kidney disease?

1 Answer available

What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?

1 Answer available

Are recurrent UTIs a contraindication to SGLT2i use?

4 Answers available

How many days prior to surgery do you recommend stopping SGLT2 inhibitors and when is it safe to resume therapy?

1 Answer available

How do you approach managing patients with diabetic kidney disease and proteinuria who develop hypoglycemia after initiation of a SGLT2 inhibitor?

1 Answer available

How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?

ESPRIT Trial

1 Answer available

How do you adjust your management strategy to address the unique needs of anuric end-stage kidney disease patients when treating diabetic ketoacidosis?

1 Answer available

Should GLP1 R agonists be used as first line glucose lowering agents in patients with ESKD and DM2?

1 Answer available

Papers discussed in this category

Lancet (London, England), 2024 Jun 27

Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.

N Engl J Med, 2015 Nov 09

A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Diabetes care, 2025 Jan 01

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025.

The lancet. Diabetes & endocrinology, 2025 Feb 13

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.

Related Topics in Nephrology